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Summary
Elderly individuals who lived beyond the age of 90 years
without dementia were hypothesized to have increased
concentrations of genetic protective factors against Alz-
heimer disease (AD), conferring a reduced liability for
this disease relative to less-aged nondemented elderly.
However, testing this hypothesis is complicated by hav-
ing to distinguish such a group from those who may lack
genetic risk factors for AD, have had protective envi-
ronmental exposures, or have escaped dementia for
other reasons. Probands carrying genetic protective fac-
tors, however, should have relatives with lower illness
rates not only for earlier-onset disease, when genetic risk
factors are a strong contributing factor to the incidence
of AD, but also for later-onset disease, when the role of
these factors appears to be markedly diminished. AD
dementia was assessed through family informants in
6,660 first-degree relatives of 1,049 nondemented pro-
bands aged 60–102 years. The probands were grouped
by age (60–74, 75–89, and 90–102 years), and the cu-
mulative survival from AD and 10-year–age-interval
hazard rates of AD were calculated in their first-degree
relatives. Cumulative survival from ADwas significantly
greater in the relatives of the oldest proband group (aged
90–102 years) than it was in the two younger groups.
In addition, the reduction in the rate of illness for this
group was relatively constant across the entire late life
span. The results suggest that genetic factors conferring
a lifelong reduced liability of AD may be more highly
concentrated among nondemented probands aged 90
years and their relatives. Efforts to identify protective
allele–bearing genes that are associated with very
late–onset AD should target the families of nonagenar-
ians and centenarians.
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Introduction
A small number of genes (e.g., the apolipoprotein E
[APOE] gene) have been associated with Alzheimer dis-
ease (AD) and possess alleles conferring different levels
of risk for this disease. Whereas an allele may be con-
sidered a “genetic risk factor” when it increases the pre-
disposition to disease relative to some other, usually
more common allele for the same gene (e.g., APOE-e4
relative to APOE-e3 [Corder et al. 1993; Farrer et al.
1997]), a “genetic protective factor” is an allele asso-
ciated with a reduction in risk relative to a more common
reference allele. In AD, the only well-established genetic
protective factor is APOE-e2 (Chartier et al. 1994;
Corder et al. 1994), but there may be other, as yet un-
identified protective alleles against AD that are present
at other loci.
Although investigative strategies such as association
studies are available to examine specific candidate genes,
a more general and powerful search for AD-related genes
with protective alleles is hampered by the age at onset
typical of the disease. The incidence of AD increases
substantially with age. In the United States, the incidence
appears to double approximately every 5 years, from
∼0.6% at 65–69 years to 8.4% at 85 years (Hebert
et al. 1995). Thus, the absence of the AD phenotype in
individuals living well into the eighth or the early part
of the ninth decade of life does little more than margin-
ally increase the likelihood that such individuals carry
a liability to AD less than that in the general population.
Even in the very longest–lived nondemented individuals,
assessing the possibility that they may carry particular
alleles that are protective against AD is complicated by
various other possibilities. For example, such individuals
may lack genetic risk factors or exposure to environ-
mental ones, or they may have had protective environ-
mental exposures or escaped AD for other reasons.
The investigation of families of aged, nondemented
probands may help to narrow these alternatives and aid
in identifying individuals within families who are more
likely to carry genetic protective factors against AD. In
an earlier genetic epidemiological study, relatives of op-
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timally healthy nondemented probands aged 85 years
were found to have a reduced risk of dementia compared
with the relatives of younger but still elderly random
controls (Payami et al. 1994). This finding suggests that
familial—likely genetic—factors help to explain these
probands’ freedom from AD (at least until the ages at
which they were studied). However, detecting a differ-
ence between survival curves does not by itself help to
distinguish between increased genetic protective factors
and decreased genetic risk factors.
In the present study, we assessed the survival from AD
in the relatives of a group of nondemented probands
who had lived beyond age 90 years, that is, well into
the ages of highest incidence of AD, and in relatives of
other nondemented, but younger, probands. Similar to
earlier investigators in this area, we compared survival
curves among the relatives of probands from different
age groups. These curves, however, represent the cu-
mulative decreased survival from AD over time, and
hence do not adequately reveal more age-specific risk
patterns (Singer and Willett 1991). For this reason, we
also examined the patterns of risk in relatives of proband
groups at different age intervals to help identify the fac-
tors that likely underlie any detected differences in the
overall curve. A reduced frequency of genetic risk factors
should lead to lower rates of relatively earlier-onset ill-
ness, when such factors most strongly influence the ex-
pression of AD (Silverman et al. 1994). An increased
frequency of genetic protective factors should lead to
lower rates of later-onset illness as well, when the role
of genetic risk factors appears to be greatly diminished.
Subjects and Methods
Index Subjects
Family histories were collected from 1,049 elderly
probands who were nondemented and aged 160 years.
The probands were recruited from the following sources:
(1) the spouses of geriatric probands involved in studies
at the Mt. Sinai Alzheimer’s Disease Research Center
( ); (2) nondemented residents at the Jewishn  292
Home and Hospital for Aged (JHHA) ( ); (3)n  135
spouses of JHHA residents ( ); and (4) Jewishn  200
and Italian participants in New York City–sponsored
senior centers ( ) (Silverman et al. 1992). Al-n  422
though the probands in the latter three groups were more
ethnically homogeneous than those in the first group,
the cumulative risk curves for AD in their relatives have
been found to be almost identical (Silverman et al. 1994),
justifying their inclusion in a single, nondemented pro-
band group. Determination that these index subjects
were free of dementia was made by evaluation with the
Alzheimer’s Disease Risk Questionnaire (ADRQ) (Breit-
ner and Folstein 1984) and the Dementia Questionnaire
(DQ) (Silverman et al. 1986), described below, admin-
istered to one or two family informants. The probands
were grouped, according to their age at the time of the
interview, into three 15-year age intervals: 60–74,
75–89, and 90–104 years. All protocols used were ap-
proved by the Mt. Sinai Institutional Review Board.
Assessment of Relatives
We identified first-degree relatives of the probands by
using the ADRQ, and we collected information on each
relative concerning birth year, sex, current age (if alive),
or (if not) age at, and cause of, death. Finally, the ADRQ
was used to screen for possible dementia, cognitive im-
pairment, or memory loss of any type. If any such con-
dition was suggested, the DQ was administered for that
relative. The DQ is a 50-item questionnaire focused on
ascertaining whether a dementia is present and, if so,
determining its specific type. AD was diagnosed accord-
ing to previously published criteria (Silverman et al.
1986) that are similar to DSM-IV criteria for dementia
of the Alzheimer type (American Psychiatric Association
1994) but designed for informant-based assessment. Pre-
vious studies have found this method to have very good
interinformant (Silverman et al. 1986) and test-retest
(Silverman et al. 1990) reliability. The DQ has dem-
onstrated excellent sensitivity and specificity for identi-
fying dementias independently ascertained through di-
rect clinical assessment (Kawas et al. 1994). In addition,
in a study of a series of former nursing home residents,
informant-based DQ diagnoses were compared with in-
dependent neuropathological examinations; for AD, the
family history method was found to be only slightly less
sensitive than direct clinical assessment, and its specific-
ity was virtually at the same level (Li et al. 1997).
Statistics
In addition to conventional x2 and analysis of vari-
ance, the actuarial life table method was used with
1-year intervals to generate survival curves for AD in
relatives. Survival analysis provides an estimate of the
cumulative rate of survival from AD over time and al-
lows rates in different groups to be compared while dif-
ferences in age structure are controlled for. As described
more fully elsewhere (Silverman et al. 1994), in contrast
to the Kaplan-Meier method, the actuarial method in-
cludes an estimation of within-interval censorship,
which, when the interval is minimized, likely improves
the survival estimate. The Mantel-Haenszel log-rank sta-
tistic was used to test the difference between curves. In
addition to statistical comparisons of survival curves, the
test of the difference between two proportions (z statis-
tic) was used to determine whether groups differed in
the cumulative survival estimate at a point on the curve,
specifically at the age of 90 years. We also calculated
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Figure 1 Cumulative survival of AD dementia in relatives of
probands aged 60–74, 75–89, and 90–102 years.
Table 1
Demographic Characteristics of Nondemented Probands and Their Relatives
Age
Gr-
oup
NONDEMENTED PROBANDS FIRST-DEGREE RELATIVES
No. of
Individuals
Mean
Age (SD)
Women
(n [%])a
No. of
Individuals
Mean
Age (SD)b
Women
(n [%])c
AD Dementia
(n [%])d
Age (SD)
at Onsete
60–74 478 68.7 (3.9) 275 (57.5) 3,018 61.4 (19.1) 1,466 (48.6) 57 (1.9) 76.1 (9.1)
75–89 486 80.5 (3.9) 280 (57.6) 3,050 65.3 (18.9) 1,498 (49.2) 71 (2.3) 79.1 (7.9)
90–102 85 93.5 (3.1) 56 (65.9) 592 70.1 (18.2) 300 (50.8) 7 (1.2) 81.1 (9.9)
Total 1,049 76.2 (8.6)f 611 (58.2) 6,660 63.9 (19.1)f 3,269 (49.0) 135 (2.0) 78.0 (8.6)f
NOTE.—All ages are given in years.
a x2  2.22, , NS.df  2
b , .F(2,6238) 65.77 P ! .001
c x2  .96, , NS.df  2
d x2  .45, , NS.df  1
e , NS.F(2,131) 2.47
f Mean (SD).
the 10-year–age-interval hazard rates for each group of
relatives. This statistic provides an estimate of the risk
of AD a relative faces per year during a given age in-
terval, given that the relative is alive and at risk at the
start of the interval. The hazard-rate ratio is a measure
of the extent to which one hazard rate is increased or
decreased in comparison to another (reference) hazard
rate. The hazard-rate statistics and the hazard-rate ratios
were calculated primarily as an internal diagnostic tool.
Using the relatives of the youngest proband group (aged
60–74 years) as a reference group, we could inspect the
set of decade-specific hazard-rate ratios for each of the
other two groups. Examining the degree to which these
ratios were similar across different age intervals would
help reveal whether a difference in survival curves de-
rived from proportionately similar levels of increased
risk across the late life span or whether the overall dif-
ference might instead have been disproportionately
driven by increased rates at particular age periods.
Results
Demographic and diagnostic information was as-
sessed in 6,660 first-degree biological relatives of 1,049
nondemented elderly probands (table 1) aged 60–102
years (hence the oldest proband group was redesignated
“90–102 years”). Across the three groups, the propor-
tions of women among the probands and their relatives
were similar. As expected, the relatives of these succes-
sively older proband groups were themselves succes-
sively older. Using the crude proportion of AD cases in
each group of relatives (i.e., with no correction for age
structure), we found no significant differences, nor did
we find significant differences in mean age at onset.
The survival curves for the three groups of relatives
(fig. 1) were significantly different (log-rank statistic 
9.8, , ). In pairwise comparisons, the over-df  2 P ! .01
all survival from AD observed in the relatives of the
nondemented probands aged 90–102 years was signifi-
cantly better than the survival observed both in the rel-
atives of probands aged 60–74 years (log-rank statistic
 9.3, , ) and in the relatives of probandsdf  1 P ! .005
aged 75–89 years (log-rank statistic  7.9, ,df  1
). In contrast, the survival curves associatedP  .005
with the two younger proband groups did not signifi-
cantly differ (log-rank statistic  0.8, , not sig-df  1
nificant [NS]). By the age of 90 years, cumulative sur-
vival from AD was 96.0% 1.7% SD among relatives
of probands aged 90–102 years. This rate of survival
was significantly better than that found in the relatives
of probands aged 60–74 years (87.4%  2.0% SD;
, ) and in the relatives of probands agedz  3.16 P ! .005
75–89 years (89.5%  1.4% SD; , ).z  2.88 P ! .005
The latter two groups did not differ significantly (z 
, NS).0.81
In the fifth through ninth decades, there were new AD
cases in one or more of the groups and sufficient num-
bers of relatives still at risk ( in each group) ton 1 100
provide a reasonably stable hazard-rate estimate (fig. 2).
In the fifth and sixth decades, the hazard rate rose above
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Figure 2 Ten-year–age-interval–specific hazard rates of AD de-
mentia in relatives of probands aged 60–74, 75–89, and 90–102 years.
Figure 3 Ten-year–age-interval–specific hazard-rate ratios in rel-
atives of probands aged 75–89 and 90–102 years compared with rel-
atives of probands aged 60–74 years.
zero only in the relatives of the probands aged 60–74
years. In subsequent decades, the hazard rate rose in each
group with increasing steepness. In the seventh decade,
the rates of AD were still noticeably higher in the rel-
atives of the youngest proband group than in those of
the two older groups, whose rates were similar to each
other. The low base rates of AD at these ages reduce
power, and these differences were not significant. In the
eighth and ninth decades, the hazard rates of the relatives
of probands aged 90–102 years were significantly lower
than those of the relatives of probands aged 60–74 years
(eighth decade, , ; ninth decade,z  2.03 P ! .05 z 
, ) and those of relatives of probands aged2.84 P ! .005
75–89 years (eighth decade, , ; ninthz  2.23 P ! .05
decade, , ).z  2.98 P ! .005
Using the relatives of the probands aged 60–74 years
as the reference group, we then assessed the 10-year–age-
interval–specific hazard-rate ratios for the seventh,
eighth, and ninth decades—the three age intervals for
which these could be meaningfully calculated (fig. 3).
Here we were primarily interested in the relatives of the
oldest proband group, because only this group had a
survival curve significantly different from the reference
group’s. Again, statistical power was low for these com-
parisons; only for the ninth decade was the hazard-rate
ratio significantly different from 1.0 (hazard-rate ratio
 0.26; 95% confidence interval  0.08–0.85). How-
ever, the primary purpose for calculating the hazard-rate
ratios was to determine whether the overall difference
observed in survival curves was driven by proportion-
ately similar levels of decreased risk across different age
periods. That this was so is indicated by the essentially
flat line associated with the relatives of the oldest pro-
band group. Although the survival curve for the relatives
of probands aged 75–89 years was not significantly dif-
ferent from the reference group’s, for comparison pur-
poses, we also included their hazard-rate ratios. None
of these were significantly different from 1.0, but, rel-
ative to each other, the hazard-rate ratio in the seventh
decade was lower than those in the two subsequent
decades.
The 15-year intervals for grouping the probands were
relatively wide time periods. Might the familial char-
acteristics of those probands with ages closer to the di-
viding point (age 90 years) be more similar to each other
than was observed in the full group comparisons? To
answer this question, we identified the subgroups of pro-
bands whose ages fell in the 5 years immediately below
(85–89 years: ) or above (90–94 years: )n  92 n  63
the dividing point of age 90 years and compared the risk
of AD in their respective relatives (85–89 years: n 
; 90–94 years: ) with the risk in relatives of564 n  357
the probands aged 60–74 years and with that of each
other’s relatives. Compared with the reference group,
the relatives of the probands aged 90–94 years (log-rank
statistic  5.3, , ), but not those of the pro-df  1 P ! .5
bands aged 85–89 years (log-rank statistic  0.0,
, NS), showed better survival from AD, and thedf  1
latter two curves were also significantly different from
each other (log-rank statistic  4.2, ,df  1
).P ! .05
We were able to examine APOE genotypes in only a
small subset of probands ( ), but we found non  133
significant differences between groups (x2 7.3, df 
, NS). The allele frequencies of APOE-e2 were roughly10
similar (0.11, 0.08, and 0.10 in probands aged 60–74,
75–89, and 89–102 years, respectively), as were the al-
lele frequencies of APOE-e4 (0.14, 0.13, and 0.11 in
probands aged 60–74, 75–89, and 90–102 years,
respectively).
Discussion
The relatives of nondemented probands who had lived
to the 10th decade or beyond had a significantly lower
risk of AD compared with relatives of two groups of
successively younger, but still elderly, nondemented pro-
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bands. In addition, the reduction in risk among the rel-
atives of the oldest proband group encompassed virtu-
ally the entire late life span. In contrast, similar to
nondemented probands’ relatives described elsewhere
(Payami et al. 1995; Mayeux et al. 1991; Hirst et al.
1994), AD in the relatives of the two younger groups
of probands decreased to !90% by the age of 90 years.
Two different, but not mutually exclusive, possibilities
provide the most obvious explanations for the reduction
in risk of AD among relatives of the oldest nondemented
probands. First, nonagenarian and centenarian pro-
bands have lived through more of the risk period for
AD free of disease, and hence are less likely to carry
alleles that might either directly cause AD (Goate et al.
1991; Levy-Lehad et al. 1995; Sherrington et al. 1997)
or, more generally, increase the risk of AD (e.g., APOE-
e4) (Corder et al. 1993). This is especially likely since
the pattern of risk among relatives of AD probands sug-
gests that genetic risk factors are less influential with
increasing age and that their effects are markedly di-
minished by the ages of peak incidence (Heun and Maier
1995; Li et al. 1995; Silverman et al. 1994; Lautensch-
lager et al. 1996). Consistent with this, several recent
studies of APOE-e4 (Scacchi et al. 1995; Sobel et al.
1995; Asada et al. 1996; Corder et al. 1996; Blacker et
al. 1997; Farrer et al. 1997)—but not all (Brayne et al.
1996; Gessner et al. 1997; Payami et al. 1997)—have
found that the effect of this allele on AD markedly di-
minishes at very late ages.
A second possible explanation for lower rates of AD
among the relatives of long-lived nondemented probands
is that such probands are more likely to carry genetic
protective factors. Although some candidates (e.g., hu-
man leukocyte DR4 or DR6 antigens [Sandbrink et al.
1996; Curran et al. 1997]) have been suggested, the ev-
idence seems strongest for the APOE-e2 allele (Chartier
et al. 1994; Corder et al. 1994; Higgins et al. 1997). A
recent meta-analysis found the odds ratio for AD among
individuals with e2/e2 or e2/e3 APOE genotypes was 0.6
compared with individuals carrying a e3/e3 genotype
(Farrer et al. 1997). Yet, there may well be alleles on
other genes, or possibly nongenetic familial factors, thus
far unidentified, that confer protection against AD (Pay-
ami et al. 1994). If indeed genetic, such protective alleles,
provided they are not positively associated with some
competing fatal illness, will tend to be more highly con-
centrated among long-lived nondemented individuals,
since these individuals have manifestly remained free of
dementia over a very long stretch of the risk period,
including many years of peak incidence. In turn, by
Hardy-Weinberg equilibrium, their relatives will have a
higher concentration of such genes than the relatives of
nondemented probands who have not lived so long into
the risk period.
The patterns of risk in the present study offer some
useful clues for estimating the contribution of genetic
protective factors to the observed reduced risk. Reduced
rates of earlier-onset illness can be expected from a group
that primarily lacks a high concentration of genetic risk
factors for AD but does not possess a high concentration
of genetic protective factors. The liability to later-onset
disease in such a group would tend, with age, to in-
creasingly resemble that of the general population. Such
a pattern was observed for relatives of probands aged
75–89 years. It must be emphasized that the survival
curve in this group did not significantly differ from that
of the reference group, nor did any of the age-interval
hazard rates. Thus, the pattern of hazard-rate ratios,
suggestive of lower rates of earlier- but not later-onset
AD, must serve strictly as an interesting hypothesis that
requires further testing with a larger sample.
On the other hand, the statistically significant reduc-
tion of risk for AD in the relatives of the probands aged
90 years appeared to be essentially consistent over a
30-year span of late life. This suggests a reduced inci-
dence not only of AD variants attributable to genetic
risk factors, but also of those types of disease in which
the role of genetic risk factors appears to be markedly
diminished. Thus, the concentration of genetic factors
that protect against AD is likely to be substantially in-
creased among the families of nondemented individuals
living into the 10th decade, particularly among those
very old individuals themselves, compared with families
of other, less aged individuals.
The cumulative survival differences observed in the
present study are similar to those observed in an earlier
study that compared relatives of optimally healthy, non-
demented individuals aged 85 years with relatives of
a younger group of random controls (Payami et al.
1994). The results of the present study, which used a
sample that overall is 110 times as large as the nonde-
mented proband sample used previously, extend the find-
ings from the earlier study by examining age-inter-
val–specific patterns of risk. Another difference in the
present study was our choice of the age of 90 rather
than 85 years as a dividing age. This was done to ex-
amine the families of individuals who had lived well into
the years of peak incidence of AD without having de-
veloped the disease. Thus, it was informative to restrict
the ranges of proband ages to 85–89 and 90–94 years
and observe that the results in these more narrowly de-
fined and adjacent age–determined subgroups were sim-
ilar to the larger, more broadly based age groups. In a
post hoc analysis (data not shown), we confirmed that
using the age of 85 rather than 90 years as the di-
viding point would also have led to significant overall
differences, more directly replicating the results of Pay-
ami et al. (1994), but the age-specific risk of AD in this
more broadly defined proband group was dispropor-
tionately reduced at earlier ages and then rose during
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later decades to levels more comparable to those of rel-
atives of younger nondemented probands.
Several methodological issues require attention. First,
it is possible that these results may have arisen from
different levels of accuracy, associated with increased
proband age, about AD among family members. Al-
though such a bias cannot be ruled out, the particular
pattern of results obtained does not readily lend itself
to such an interpretation. For example, the survival
curve of relatives of probands as old as 85–89 years was
quite different from that of relatives of an only slightly
older proband group but was similar to that of the rel-
atives of the substantially younger proband group.
A second issue is whether APOE-e2 alone can explain
the reduced rates of AD in the relatives of the oldest
probands—without having to posit other, yet to be iden-
tified, protective alleles of other genes. This possibility
is refuted by the low and similar frequencies of APOE-
e2 in the smaller subgroups of probands that could be
genotyped. At the same time, the failure to find differ-
ences in the e2 allele frequency should not be interpreted
as important evidence against this allele’s protective
properties. The absence of an age-related relationship in
this relatively small sample must be weighed against the
size and consistency of those studies associating APOE-
e2 with greater longevity and freedom from dementia
(Corder et al. 1996; Helkala et al. 1996; Farrer et al.
1997). Even among centenarians, the absolute frequency
of APOE-e2 has been observed to be low, even though
it is greater than in younger groups (Hirose et al. 1997).
Hence, rather large samples are generally required, to
detect differences between the oldest old and younger
elderly groups.
Third, although our methods for determining the ab-
sence of dementia in probands have been shown to have
very good to excellent reliability and validity, they are
inevitably less certain than a full cognitive evaluation.
Any misclassification of probands that might have oc-
curred, however, would likely be strongly associated
with age. This, in turn, would mean that the observed
rate of survival from AD in the relatives of the oldest
nondemented probands may have been unduly deflated
by the inclusion of some relatives of probands with de-
mentia; the true rate of survival might be even better in
this group than what was observed.
The findings from the present study suggest that var-
iation in familial liability to AD exists even at ages at
which the role of genetic risk factors appears to be small.
Some families have a relatively low risk of AD through-
out the life span. If this is so, it presents opportunities
to identify genes involved in the pathogenesis of some
of the most common forms of AD that, perhaps because
of the apparent ubiquity of the alleles associated with
AD vulnerability at those ages, may be otherwise difficult
to ascertain. In AIDS research, a mutation of the CC-
CKR-5 gene that is resistant to HIV has recently been
identified by focusing on a group of individuals repeat-
edly exposed to HIV who yet remained free of infection
(Dean et al. 1996; Liu et al. 1996). In a search for AD-
associated genes with uncommon protective alleles, the
present results suggest that it may be valuable to study
probands who have lived at least to the 10th decade
without developing dementia. Future genetic studies
(e.g., an unaffected sibling pair approach in which both
siblings are required to be free of AD) aimed at identi-
fying such genes might benefit from targeting such pro-
bands and their families.
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